Institut Carnot OPALE

Driving innovation through public-private partnerships 🤝 𝗣𝘂𝗯𝗹𝗶𝗰-𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 are pivotal in accelerating research breakthroughs in the field of leukemias (e.g. #AML, #ALL) and related diseases (e.g. #MDS and #MPN). By 𝗰𝗼𝗺𝗯𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗼𝗳 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗰 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀, these collaborations 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗮𝘁𝗲 𝘁𝗵𝗲 𝗿𝗮𝗽𝗶𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 of new therapies and diagnostics. 🔬 Such partnerships range 𝗳𝗿𝗼𝗺 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, enabling resource sharing and expertise that are vital for translating discoveries into real-world treatments. They foster a 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁 where diverse perspectives drive innovation and improve patient outcomes. 🚀 Key benefits of public-private partnerships: 👉 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻: Merging academic and industry strengths to advance research. 👉 𝗥𝗲𝘀𝗼𝘂𝗿𝗰𝗲 𝗦𝗵𝗮𝗿𝗶𝗻𝗴: Leveraging shared resources to bring innovations to market faster. 👉 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Combining diverse perspectives to drive forward-thinking solutions. At #LEUKEMIA360, we will explore the power of these collaborations in accelerating innovation. Attendees will 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗯𝗲𝘀𝘁 𝗥&𝗗 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀, discover new collaboration opportunities, and contribute to shaping the future of leukemia treatment and diagnosis. By participating, you will have the chance to 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗹𝗲𝘂𝗸𝗲𝗺𝗶𝗮 𝗲𝘅𝗽𝗲𝗿𝘁𝘀, learn about a cutting-edge research and development offer, and explore the transformative potential of partnerships jointly presented by academia and industry. 🌟 Network with pioneers and explore how 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗲𝗳𝗳𝗼𝗿𝘁𝘀 𝗰𝗮𝗻 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, allow earlier diagnosis and bring new, more personalized therapies to leukemia patients faster. #Leukemiatherapy #Leukemiadiagnosis #PublicPrivatePartnerships #Innovation #Leukemia360 Le Réseau des Carnot / Advesya / THEMA Saint-Louis Leukemia Institute / AP-HP, Assistance Publique - Hôpitaux de Paris/ Paris Saclay Cancer Cluster (PSCC) / Institut Paoli-Calmettes / Université Paris Cité / OncoSTART Pascal Deschaseaux / Hervé Dombret / Marina Konopleva / Robert Zeiser / Sylvie Freeman / Richard C. A. Sainson / Jian-Qing Mi / Hugues de Thé / Florian Heidel / Virginie Gandemer / Norbert VEY / Jean-Emmanuel Sarry / François Delhommeau / Raphael Itzykson / Stephanie Fugain / Jean-Pierre Bizzari

Transforming leukemia treatment: 𝗜𝗻𝘀𝗶𝗱𝗲 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 ⬇️ CAR-T cell therapy represents 𝗮 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗹𝗲𝗮𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 in leukemia treatment. This innovative approach involves reprogramming a patient's own T-cells to seek out and destroy cancerous cells, offering new hope for those affected by several cancers, including leukemia, deadliest blood cancer and first child cancer. 🔬 𝗪𝗵𝘆 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: 1️⃣ 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: Tailors therapy to the individual, improving efficacy and safety. 2️⃣ 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗦𝗰𝗶𝗲𝗻𝗰𝗲: Continues to evolve, moving from experimental to clinical application. 3️⃣ 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗜𝗺𝗽𝗮𝗰𝘁: Offers new possibilities where traditional therapies may not be effective. To delve deeper into the latest innovations in CAR-T cell therapy, 𝗷𝗼𝗶𝗻 𝘁𝗵𝗲 𝗼𝘁𝗵𝗲𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 𝗮𝘁 𝗟𝗘𝗨𝗞𝗘𝗠𝗜𝗔 𝟯𝟲𝟬 on November 13th in Paris. This event will bring together leading experts in the leukemia field to present new research avenues, and discuss future directions for drug development. Among other therapeutic options, the comprehensive CAR-T R&D offer of Institut Carnot OPALE, the Organization for Partnerships in Leukemia, will be presented and discussed at a devoted workshop, while an example of public-private CAR-T cell development partnership will be discussed. OPALE is a member of Consortium national de recherche sur les thérapies cellulaires et géniques (UNITC), a France’s National Cancer Institute-labelled National Research Network on CAR-T Cells and Other Innovative Gene Therapies in Oncology. On site, 𝗽𝗿𝗲-𝗯𝗼𝗼𝗸𝗲𝗱 𝟭:𝟭 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻𝘀 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗮𝗻 𝘂𝗻𝗿𝗶𝘃𝗮𝗹𝗲𝗱 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝘄𝗶𝘁𝗵 𝗽𝗶𝗼𝗻𝗲𝗲𝗿𝘀, learn from their experience, and explore the transformative potential of this therapy and others. 📅 𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿 𝗮𝗻𝗱 𝗷𝗼𝗶𝗻 𝘂𝘀 for an event that promises to provide valuable insights and networking opportunities. ⚛ Be part of this new, transformative event on November 13th in Paris. #leukemia #CARTcells #innovation #ResearchandDevelopment #partnersips #OPALECarnotInstitute #UNITC Le Réseau des Carnot / Advesya / THEMA Saint-Louis Leukemia Institute / AP-HP, Assistance Publique - Hôpitaux de Paris/ Paris Saclay Cancer Cluster (PSCC) / Institut Paoli-Calmettes / Université Paris Cité / OncoSTART Pascal Deschaseaux / Hervé Dombret

🗓️ Leukemia companies: mark your calendars for November 13th in Paris!  #LEUKEMIA360 is your gateway to pioneering public-private collaborations in the field of leukemias and related diseases therapeutics and diagnostic. 💡 Why attend? - Discover breakthroughs: dive into cutting-edge research from 40 esteemed academic organizations dedicated to leukemias and related diseases - Network with leaders: engage with top-tier leukemia experts like Hervé Dombret, Marina Konopleva, Hugues de Thé, Sylvie Freeman, Richard Stone, Yang Shen and many more - Gain insights: Learn about the latest leukemia R&D advancements in targeted therapy, CAR-T cells, chemotherapy, stem cell transplantation, and immunotherapy - Know more about unique academic capabilities, platforms, models and organizations 🤝 Maximize your connections: - Attend plenary scientific talks  - Hear the voice of a leading leukemia patient advocacy organization - Discuss with researchers and clinicians at thematic R&D workshops - Participate in 1:1 meetings with leukemia opinion leaders - Join dynamic round table discussions with industry and academia representatives - Explore jointly presented successful industry-academia collaborations 🎟️ Secure your spot today as places are limited to insure maximal return on your participation (link in the comments): don't miss this unparalleled opportunity to propel your R&D efforts. #Leukemia360 #PharmaInnovation #LeukemiaResearch #PublicPrivatePartnerships #Networking #HealthcareInnovation #Pharmaceuticals #Biotech #RDEvents Le Réseau des Carnot / THEMA Saint-Louis Leukemia Institute / AP-HP, Assistance Publique - Hôpitaux de Paris / Paris Saclay Cancer Cluster (PSCC) / OncoSTART

𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗻𝗲𝘄 𝗴𝗿𝗼𝘂𝗻𝗱 𝗶𝗻 𝗹𝗲𝘂𝗸𝗲𝗺𝗶𝗮 𝗥&𝗗! 🧬 Institut Carnot OPALE, The Organization for Partnerships in Leukemia, is proud to announce a strategic partnership with the renowned Shanghai Institute of Hematology (SIH) at Ruijin Hospital (Ruijin Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine), China. 👉 This collaboration aims to drive transformative research and development projects to address global medical and industrial unmet needs in leukemias and related diseases, together the deadliest blood cancer. 🔍 Why this matters: our partnership builds on a rich legacy of leukemia research collaboration initiated at Institut de Recherche Saint-Louis (IRSL) in the 1980s by Prof. Laurent Degos, Prof. Hugues de Thé and Prof. Zhu Chen, which continued to thrive with contributions from leading experts like Prof. François Sigaux and Prof. Saijuan Chen, and more recently, Prof. Hervé Dombret and Prof. Weili Zhao. 👉 Together, thanks to the expertise of our hundreds of researchers, to our large specialized clinical networks, to our yearly access to thousands of patients, and to our unique platforms and disease models we are committed to pushing the boundaries of leukemia research. 🦾 🌍Our objective: this cooperation aligns with OPALE's strategy to build privileged, long-term relationships with a leading hematology institute in China and in the US, respectively.  👉 The goal of the present agreement is to accelerate leukemia therapeutic and diagnostic innovation along the full R&D value chain through joint research projects involving top #scientists from SIH and from the OPALE national consortium. Our scope includes all types of leukemias, myelodysplastic syndromes, myeloproliferative neoplasms and other related disorders. Concerned therapeutics are targeted therapies, CAR-T cells, chemotherapy, immunotherapy and cell therapy. 🔬 👉 We have already identified two promising projects to kickstart this initiative, for which industry partners will be sought. 📅 Mark your calendars: join us at the #LEUKEMIA360 international event in Paris on November 13. Among many other topics, we will discuss this strategic cooperation and its impact on our industrial partners interested in the leukemia market. Companies, #savethedate! #Bloodcancer #Leukemia #Therapy #Diagnosis #Research #Development #Innovation #Partnerships #OPALE #Carnot #Leukemia360 #China #ShanghaiHematologyInstitute Le Réseau des Carnot / THEMA Saint-Louis Leukemia Institute / AP-HP, Assistance Publique - Hôpitaux de Paris / Paris Saclay Cancer Cluster (PSCC) / OncoSTART

🚀 Exciting Advances in Leukemia Treatment: CAR-T Cells 🚀 At Institut Carnot OPALE, our consortium collaborates with leading entities in leukemia and related diseases, focusing on the research and development of therapeutic and diagnostic solutions. One of the most promising breakthroughs is CAR-T cell therapy. This innovative treatment reprograms a patient’s own immune cells to target and destroy leukemia cells, offering new hope for patients #worldwide. 🌏 🎙️ Want to learn more? Join us at our upcoming event, #LEUKEMIA360, where leading experts Richard C. A. Sainson & Raphael Itzykson will dive deep into the latest advancements and clinical applications of CAR-T cell therapy. #Leukemia360 #CancerResearch #CARTCells #InnovationInHealthcare #Innovation #Networking #Paris2024 #Leukemia #partnerships Le Réseau des Carnot / Advesya / THEMA Saint-Louis Leukemia Institute / AP-HP, Assistance Publique - Hôpitaux de Paris / Paris Saclay Cancer Cluster (PSCC) / OncoSTART Hervé Dombret / Pascal Deschaseaux

Don’t miss out on this opportunity to connect with experts from THEMA Saint-Louis Leukemia Institute and from around the #world! #Leukemia #Symposium #Hematology #MedicalResearch

🔬 Exciting Announcement: Join Us at LEUKEMIA 360 in Paris! 🌍 We are thrilled to announce the inaugural #LEUKEMIA360 event on November 13, 2024, in Paris! This groundbreaking event, organized by Institut Carnot OPALE and supported by France’s National Cancer Institute (Institut national du cancer), will bring together key scientific opinion leader, top-tier researchers, industry leaders, and patient advocates to discuss the latest innovations in leukemia diagnosis and treatment. Highlights: 👉 Insights from global scientific leaders 👉 Showcase of cutting-edge R&D from 40 academic organizations 👉 Opportunities for 1:1 meetings and networking Don't miss this unique opportunity to foster valuable #partnerships and accelerate advancements in leukemia research. Mark your calendars and join us in #Paris! #Leukemia360 #CancerResearch #Innovation #Networking #Paris2024 #Leukemia #MeettheLeukemiaExperts Le Réseau des Carnot / Advesya / AP-HP, Assistance Publique - Hôpitaux de Paris / Paris Saclay Cancer Cluster (PSCC) / OncoSTART / MATWIN /SiRIC InsiTu / THEMA Saint-Louis Institute / BioLaunchpad / BeiGene / Daiichi Sankyo Oncologie / TRIBVN / Institut Paoli-Calmettes Verena Voelter, MD / Richard C. A. Sainson / Hervé Dombret / Pascal Deschaseaux / Jacques KLOSSA

🚨 𝐌𝐚𝐣𝐨𝐫 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐥𝐞𝐮𝐤𝐞𝐦𝐢𝐚 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬: 𝐦𝐞𝐞𝐭 𝐭𝐡𝐞 𝐞𝐱𝐩𝐞𝐫𝐭𝐬 𝐢𝐧 𝐏𝐚𝐫𝐢𝐬! 📅 Next November 13 in Paris, at Pierre Mendès France Conference Center, don’t miss #LEUKEMIA360, a one-of-its-kind international event supported by France’s National Cancer Institute (Institut national du cancer). 👋 Organized by Institut Carnot OPALE, the Organization for Partnerships in Leukemia, chaired by Hervé Dombret, this manifestation is dedicated to 𝗽𝘂𝗯𝗹𝗶𝗰-𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 in leukemia and related diseases, focusing on therapeutic and diagnostic solutions research and development. 🌐 For the first time, 𝟰𝟬 𝗹𝗲𝘂𝗸𝗲𝗺𝗶𝗮 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗰 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝗿𝗴𝗮𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝗹𝗹 𝗴𝗮𝘁𝗵𝗲𝗿 𝘁𝗼 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗲 𝘁𝗵𝗲𝗶𝗿 𝘂𝗻𝗶𝗾𝘂𝗲 𝗥&𝗗 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗮𝗻𝗱 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀, 𝗼𝗻 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝘀𝗲𝘀𝘀𝗶𝗼𝗻𝘀, 𝗥&𝗗 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽𝘀 𝗮𝗻𝗱 𝟭:𝟭 𝗺𝗲𝗲𝘁𝗶𝗻𝗴𝘀. 👨⚕️👩⚕️ Key scientific opinion leaders from Europe, USA and China will discuss the latest trends in the field, such as Marina Konopleva, Robert Zeiser, Sylvie Freeman, Rich Stone, Jian-Qing Mi, Hugues de Thé, Florian Heidel, Virginie Gandemer, Norbert VEY, Jean-Emmanuel Sarry, François Delhommeau, Raphael Itzykson, many more… 🗣️ You will also hear from: Stephanie Fugain, Chairwoman of Association Laurette Fugain, the leukemia patients' voices; from INCa Chairman Norbert Ifrah what the institute does to support French excellence in #leukemia research. 👨🏫 Round tables will be organized and success stories presentations will involve healthcare company representatives. Jean-Pierre Bizzari will speak on that occasion. 🤝 Many partnership opportunities are to be seized during this groundbreaking event aimed at industry professionals (#pharma, #biotech, #medtech, #diagnostic, #data #AI)… Pre-registration on www.leukemia360.org 🇬🇧 The event will be in English language and will be moderated by Verena Voelter, MD, CEO, Founder of 5P Health Care Solutions. If you are tagged in this post, please consider sharing 🔀 Pascal Deschaseaux / Le Réseau des Carnot / OncoSTART / BioLaunchpad, Paris Saclay Cancer Cluster (PSCC), ANR (Agence nationale de la recherche) / Dr. Jean-Michel Le Roux / Dr. Jean-Denis MULLER / Alexandre Bounouh, MBA, PhD, HDR #Carnot #PartneringResearch #Health #Innovation #DataScience #Networking

🎓 2ème édition de l'OncoSTART Entrepreneurship School ⬇️ 👨⚕️ Cette école dédiée à l’entrepreneuriat en #oncologie, est destinée à accompagner une quinzaine de porteurs de projet dans la définition de leur Business Model. ➡️ Elle a été conçue et organisée spécialement par les 14 organisations membres du consortium OncoSTART (experts de la recherche et l’innovation cancer). L'Institut Carnot OPALE, the Organization for Partnerships in Leukemia, est l'un d'entre eux: en tant que co-fondateur d'OncoSTART et partenaire de BioLaunchpad, nous soutenons l'entrepreneuriat. 💪 Au travers de cette formation accélérée (5 jours), les participants bénéficieront des expertises complémentaires de près de 40 intervenants ainsi que de coaches pour les aider à passer de la théorie à la pratique ! A la fin de la semaine, ils auront l’opportunité de présenter leur projet devant un panel pluridisciplinaire de personnalités qualifiées. 🤝 OPALE pourra soutenir financièrement cette participation pour les startups ayant un projet de développement dans les leucémies ou maladies apparentées en partenariat avec notre institut (nous contacter si intéressés)

Merci Gilead Sciences France 💜🙏